Neogenomics Inc. (NEO - Free Report) is a provider of genetic and molecular testing services that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NEO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Neogenomics could be a solid choice for investors.
Current Quarter Estimates for NEO
In the past 30 days, 3 estimates have gone higher for Neogenomics no downward movement in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 7 cents a share 30 days ago, to earnings of 2 cents today today.
Current Year Estimates for NEO
Meanwhile, Neogenomics’s current year figures are also looking quite promising, with 3 estimates moving higher in the past month, with no downward movement. The consensus estimate trend has also seen a boost for this time frame, increasing from a loss of 28 cents per share 30 days ago to earnings of 8 cents per share today.
Bottom Line
The stock has also started to move higher lately, adding 18.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Neogenomics Inc. (NEO - Free Report) is a provider of genetic and molecular testing services that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NEO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Neogenomics could be a solid choice for investors.
Current Quarter Estimates for NEO
In the past 30 days, 3 estimates have gone higher for Neogenomics no downward movement in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 7 cents a share 30 days ago, to earnings of 2 cents today today.
Current Year Estimates for NEO
Meanwhile, Neogenomics’s current year figures are also looking quite promising, with 3 estimates moving higher in the past month, with no downward movement. The consensus estimate trend has also seen a boost for this time frame, increasing from a loss of 28 cents per share 30 days ago to earnings of 8 cents per share today.
Bottom Line
The stock has also started to move higher lately, adding 18.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Get the latest research report on NEO - FREE